Key TakeawaysEli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' weight-loss drugs in government-backed healthcare plans.The proposal recommended drugs like Ozempic and Mounjaro be covered under Medicare and Medicaid, making them more accessible to millions of new patients.The White House said the changes could also lower costs of the drugs. Eli Lilly (LLY) and Novo Nordisk (NVO) shares rose Tuesday after the Biden administration propos ...

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...

After flying high during the first half of the year, pharmaceutical giant Eli Lilly (LLY -0.26%) has lost some momentum; the company's shares are down by 11% since June 1. However, the healthcare leader still has plenty of fans on Wall Street, including Israel Englander, the billionaire owner of Millennium Management, a hedge fund.Millennium Management's stake in Eli Lilly increased by 86% in the third quarter. Should you follow Englander's lead and increase your stake (or initiate a position) in Eli Lilly? ...

It's always a great time to invest in quality businesses that can prime your portfolio for long-term growth. It's important to be selective with the companies that you add to your portfolio and ensure that you only put cash into investments that align with your overall investment priorities, risk tolerance, and long-term goals.You should also only put cash to work that you can leave in your portfolio for a few years, not funds that you might soon need for bills or other financial obligations. On that note, ...

Eli Lilly and Co. LLY has seen better days. The stock is up 26.04% for the last year but has struggled recently, falling 17.57% over the last month. Chart created using Benzinga ProLilly stock is well below its summer highs and is trading at $746.94 at the time of writing. The once red-hot obesity drugmaker is in the crosshairs of bearish technicals and political uncertainty.Could the selloff be an overreaction?Read Also: Eli Lilly, Verge Genomics Opt To Develop ALS Drug CandidateBearish Signals Galore For ...

— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of the Robust Predictive Power of CONVERGE® - 83% of Prioritized Targets were Validated in Disease-Relevant Models, a Rate Significantly Higher than Industry Standards SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug disc ...

Eli Lilly (LLY) announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) or Lp(a) levels in adults with high risk of cardiovascular events in a 12-week phase II study.In the study, muvalaplin led to a significant reduction in elevated Lp(a) levels compared to placebo, meeting the study’s primary endpoint of percent change in Lp(a) from baseline to week 12.  Using an intact Lp(a) assay, the reductions in Lp(a) levels were 47.6% for the 10 mg dose, 81.7% ...

Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 studyThese data were published in the Journal of the American Medical Association (JAMA) and simultaneously presented today at the American Heart Association (AHA) Scientific Sessions 2024INDIANAPOLIS, Nov. 18, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally ...

INX-315, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio® (abemaciclib) and fulvestrant Combination therapy to be evaluated as part of ongoing Phase 1/2 study in patients with HR+/HER2- metastatic breast cancer Incyclix will sponsor the trial and Lilly will provide Verzenio Incyclix plans to initiate combination cohorts with INX-315 in fourth quarter of 2024 RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle ...

The drugmaker Ely Lilly (LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well this year, rising roughly 36% (as of Nov. 14), ahead of the broader market.Given that Eli Lilly has been public for roughly seven decades, it's no surprise that it has conducted a few stock splits. When a company does a split, the amount of a shareholder's equity doesn't change but the number of shares does. Comp ...